For Release: January 6, 2010
David Corriveau, Media Relations Officer, Dartmouth Medical School, at David.A.Corriveau@Dartmouth.edu or 603-653-0771
Reviewers cite Dartmouth CF study
Lebanon, N.H.—Reviewers for Faculty of 1000 Medicine praised a recent study by Dartmouth Medical School's lung and microbiology labs as one of the most important articles of 2009 in the search for treatments of cystic fibrosis.
Working with principal investigator Bruce Stanton, Ph.D., Dartmouth Medical School researchers identified a way to prevent the kinds of bacterial infections that develop in the lungs of CF patients. In the January 2009 issue of the American Journal of Respiratory Cell and Molecular Biology, Stanton and co-authors Sophie Moreau-Marquis, Ph.D., and George O'Toole, Ph.D., reported success at killing CF infections by combining a common antibiotic with drugs designed to deprive the offending bacteria of iron (Read a complete account).
"Despite the fact that this was an in vitro study, this therapeutic approach could proceed quickly to clinical trials as all the drugs used are FDA-approved," Faculty of 1000 reviewers Katherine Hurt and Diana Bilton wrote in November of 2009. "This pre-clinical study has suggested an exciting potential alternative therapeutic approach."
The Faculty of 1000 Medicine service identifies and evaluates medical articles based on the recommendations of more than 2,000 peer-nominated researchers and clinicians. Hurt and Bilton's full review is available here.
Stanton, a professor of physiology, directs the Dartmouth Cystic Fibrosis Research Development Program and the Dartmouth Lung Biology Center. Moreau-Marquis is a research associate in the lung center, and O'Toole is an associate professor of microbiology and immunology.